Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice.
A non-exhaustive systematic review was conducted according to the three topics. No publication restrictions were imposed and the selected languages were Spanish and English. After that, a summary of the main results and findings of the review was presented and discussed during three meetings (one for each topic) with 13 medical oncologists that usually treat mRCC. At these meetings, a questionnaire on the first-line use of pazopanib in clinical practice was also drawn up. After the meetings, the questionnaire was completed by 60 specialist medical oncologists in renal cancer.
The efficacy and safety of pazopanib have been demonstrated in several clinical trials, and subsequently confirmed in studies in real-world clinical practice. In addition to its clinical benefit and good safety profile, quality of life results for pazopanib, which compare favorably to sunitinib, make it a good option in the first-line treatment of patients. Special populations have been included in studies conducted with pazopanib, and it is safe for use in elderly patients, poor functional status, kidney failure, and mild or moderate hepatic impairment, and in patients with concomitant cardiovascular disease. The results of the questionnaire have shown that pazopanib is perceived as an effective drug, in which quality of life (QoL) outcomes are valued above all.
This paper offers a comprehensive and critical summary of efficacy, tolerability, and pharmacokinetics of pazopanib in the treatment of mRCC. Pazopanib is an effective treatment with an acceptable safety profile. Its QoL and tolerability results offer certain advantages when compared with other therapeutic alternatives, and its use appears to be safe in different patient profiles.
BMC pharmacology & toxicology. 2018 Nov 26*** epublish ***
María José Méndez-Vidal, Áurea Molina, Urbano Anido, Isabel Chirivella, Olatz Etxaniz, Eva Fernández-Parra, Marta Guix, Carolina Hernández, Julio Lambea, Álvaro Montesa, Álvaro Pinto, Silverio Ros, Enrique Gallardo
Oncology Department, Maimonides Institute of Biomedical Research (IMIBIC), Reina Sofia Hospital, Córdoba, Spain., Oncology Department, Complejo Hospitalario Universitario A Coruña, ACoruña, Spain., Oncology Department, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain., Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain., Oncology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain., Oncology Department, Hospital Nuestra Señora del Valme, Sevilla, Spain., Oncology Department, Hospital del Mar, Barcelona, Spain., Medical Oncology Department, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain., Medical Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain., Medical Oncology Department, Hospital Regional de Málaga, Málaga, Spain., Medical Oncology Department, Hospital la Paz, Madrid, Spain., Oncology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain., Oncology Department, Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí I3PT. Universitat Autònoma de Barcelona, Sabadell, Barcelona, Spain. .